MDACC Study Summary SWOG-S9925 (Archived)

Study Summary
No. SWOG-S9925:.......Lung......Bonnie S. Glisson......Thoracic and Head and Neck Med

Study Summary Title



Study Summary Number:	SWOG-S9925

Study Title:	Lung Cancer Specimen Repository Protocol, Ancillary

Physician

New Patient Referral



Name:	Bonnie S. Glisson	Patients Call:	800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Dept:	Thoracic and Head and Neck Med	Referring MD Call:	800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Phone:	713-792-6363 Contact us about clinical trials

General Information



Disease Group:	Lung	Supported By:	N/A

Phase of Study:	N/A	Return Visit:	N/A

Treatment Agents:	None	Home Care:	None.

Treatment Loc:	Independent Multicenter Arrangements

Estimated Length of Stay in Houston:	N/A


Description/ Intervention:	Unavailable

Study Objectives / Outcomes

Primary:

· To establish a central lung cancer specimen repository to serve as a resource for current and future scientific studies.

· To utilize the Southwest Oncology Group clinical database to perform clinicopathologic correlation with the results of those studies.

· To test new hypotheses are they emerge.

Study Status Information



Study Activation / Registration Date:	04/12/2004

IRB Review and Approval Date:	01/23/2006

Study Type:	Laboratory

Recruitment Status:	Terminated

Projected Accrual:	80

Enrollment Eligibility

If you do not meet the enrollment eligibility, there may be other treatment options for you. Please Contact the Referral Office for more information.

Inclusion Criteria:

1) Patients must be enrolled on one of the following Southwest Oncology Group coordinated lung cancer treatment protocols: SWOG-8805, SWOG-9019, SWOG- 9416, SWOG-9509, S9900, S0003, S0023, SO126, SO124, SO220, SO222, SO327, S0310, S0339, S0342, S0341, S0435, S0509, S0429, S0533, S0526 or S0536. Participants from other groups will have been registered to other specified SWOG studies. For patients concurrently registered to S0424 and another lung treatment protocol, specimen submissions for S0424 take priority over S9925 specimen submissions if quantity is a problem.

2) Patients must submit specimens for this study as defined for the respective treatment study in Section 4.0 (General Sample Processing and Shipping Guidelines) and Section 10.0. The adequacy of tissue specimen will be determined at the time the specimen arrives at the Repository.

3) All patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines. Consent for specimen submission will be obtained and documented with consent for the appropriate treatment protocol. Current OHRP guidelines suggest that retrospective collection of parafin blocks for SWOG-8805, SWOG-9019, SWOG-9416 and SWOG-9509 maybe exempt as noted in Section 3.3.

4) At the time of patient registration, the treating institution's name and ID number must be provided to the Data Operations Center in Seattle in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered into the data base.

Exclusion Criteria:

N/A

Links

Registration Number: NCT00920010
Study Information on Clinical Trials Registry (clinicaltrials.gov)